B7-33: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (6 sections)
B7-33 and receptor context
B7-33 is a single-chain relaxin B-chain derivative investigated as a functionally selective RXFP1 agonist. It is not interchangeable with relaxin-2 or serelaxin: the native hormone has a different, two-chain disulfide-linked structure. Equal masses do not imply equal molar concentrations or signalling profiles. The name B7-33 also does not establish the counterion or actual peptide content of a particular lyophilizate.
Record the RXFP1 expression system and selected readout when reproducing an experiment. cAMP, ERK and fibrosis markers are not interchangeable activity measurements. Comparisons with relaxin require separate stocks using their respective molecular masses and matched final medium conditions. Do not add a reducing agent merely because the parent hormone contains disulfides. Choose a solvent for the verified B7-33 construct and the cell system rather than copying a recombinant-relaxin protocol.
Check B7-33 recovery after transfer from concentrated stock to dilute working buffer. Surface losses disproportionately distort low concentrations, so comparing vessels is more informative than arbitrarily increasing nominal exposure. If carrier protein is introduced to limit adsorption, include it in controls and evaluate its effects on cells. Do not collapse different signalling assays into one universal potency: functional selectivity means relative effectiveness can depend on the selected endpoint.
Why the construct has improved aqueous solubility
Hossain and colleagues reported poor water solubility of the original isolated relaxin B-chain. They shortened its N-terminal region and used the C-terminal KRSL residues to increase positive charge. Two cysteines were replaced by serines to prevent associated dimerisation and aggregation. Their resulting B7-33 was water-soluble. This explains their particular sequence, rather than every relaxin fragment.
Before preparation confirm that your material matches this construct, including terminal groups. The original peptides were synthesised as C-terminal amides and checked by RP-HPLC and mass spectrometry. A certificate describing a different form cannot inherit the original molecular mass or handling conditions automatically. Counterion and residual water also affect content; high chromatographic area purity does not establish the exact active-peptide mass.
Which assay matches the published finding
The study compared binding and cAMP in RXFP1 systems and responses in cells naturally expressing the receptor. In fibroblast models B7-33 activated pERK1/2 and increased activity of the matrix-degrading enzyme MMP-2. An RXFP1 antagonist tested receptor dependence. A weaker cAMP response in one line therefore does not automatically establish a poor stock if the endpoint concerns another pathway.
Select one consistent assay with a reference material for quality comparisons. Mechanistic experiments additionally need a receptor-dependence check. Serelaxin used as a positive control requires its own molar calculation; equal mg/mL does not mean equal molecule numbers. Avoid comparing fresh B7-33 with aged relaxin without checking both independently. Any stock carrier protein belongs in the corresponding controls and must be assessed for readout effects.
Dilution and working-medium checks
Arithmetic example: 1 mg in a final 0.50 mL gives 2 mg/mL. To make 2 mL at 0.010 mg/mL, use 10 µL stock and buffer to 2 mL. This is not a target B7-33 assay concentration. Check the final solution in the actual assay medium: water solubility does not exclude losses after transfer into salt- or protein-containing solutions. Mark concentration as nominal when analytical recovery has not been measured.
Is a reducing agent needed? The paper describes cysteine-to-serine replacement; a disulfide-relaxin formulation does not justify reducing agent for B7-33. Does improved solubility establish stock stability? No: dissolution and structural preservation are different properties. Follow the dry vial’s temperature specification, and assess the required solution interval by comparing fresh and stored aliquots. Another RXFP1 agonist’s behaviour does not establish B7-33 shelf life.
Questions about activity and recovery
Does an equal maximal response establish equal potency? No. Curve maximum and the concentration producing a specified fraction of response are different parameters. Comparing signalling endpoints helped the original study describe B7-33 functional selectivity. A single tested concentration cannot establish the whole curve or equivalence to relaxin. Report the measured endpoint and the system that produced it.
Is clarity enough for quantitative work? B7-33 charge and solubility do not eliminate surface losses. Compare samples before and after the longest planned vessel contact, using calibrated chromatography where needed. If concentration falls, distinguish emerging degradation peaks from poor recovery off surfaces. These scenarios require different procedural changes and cannot be corrected by one arbitrary adjustment factor.
Can fibrosis findings establish storage time? No. Heart and lung model effects concern biology under study conditions, not the stability of your buffer in a refrigerator. Method transfer needs the complete B7-33 form, cell source, RXFP1 verification, signal time point and aliquot history. These distinguish cell-system changes from reagent problems instead of assigning every discrepancy to an “inactive peptide.”
End of article
B7-33
for laboratory research
Packs and current prices on the product page.